GE s Deal to Hawk DiscoverX s cAMP Assays Could Boost Its GPCR Play, Frees DiscoverX Resources | GenomeWeb

GE Healthcare will exclusively distribute DiscoverX's HitHunter cAMP enzyme fragment complementation-based assays worldwide, the companies said this week.

The deal also expands GE Healthcare's exclusive rights to market the rest of DiscoverX' HitHunter product portfolio to regions outside of North America and Europe, a DiscoverX executive said.

The deal is a significant marketing shot in the arm for DiscoverX's flagship product line, and it also allows DiscoverX to focus its resources more on scientific collaborations, R&D, and product development.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.